LeClair Wealth Partners LLC Has $245,000 Stock Holdings in Edwards Lifesciences Corporation $EW

LeClair Wealth Partners LLC trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 65.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,156 shares of the medical research company’s stock after selling 6,085 shares during the quarter. LeClair Wealth Partners LLC’s holdings in Edwards Lifesciences were worth $245,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the business. Colonial Trust Co SC raised its holdings in shares of Edwards Lifesciences by 0.4% during the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after acquiring an additional 120 shares during the period. Parkside Financial Bank & Trust increased its holdings in Edwards Lifesciences by 9.8% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after purchasing an additional 130 shares in the last quarter. Prosperity Consulting Group LLC raised its stake in shares of Edwards Lifesciences by 3.2% in the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after purchasing an additional 132 shares during the period. Howard Capital Management Inc. lifted its holdings in shares of Edwards Lifesciences by 3.3% in the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after purchasing an additional 132 shares in the last quarter. Finally, NewSquare Capital LLC boosted its position in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the sale, the vice president owned 21,266 shares of the company’s stock, valued at $1,782,941.44. This trade represents a 53.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 67,804 shares of company stock worth $5,711,242 in the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 2.9%

NYSE EW opened at $85.83 on Friday. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average of $82.72 and a 200-day moving average of $81.16. The company has a market cap of $49.81 billion, a PE ratio of 46.90, a PEG ratio of 2.18 and a beta of 0.94.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same quarter in the previous year, the firm posted $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Evercore reissued an “outperform” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research report on Monday, January 5th. Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, December 5th. Citigroup reiterated a “buy” rating and issued a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Finally, Mizuho raised their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.